Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2017

  • ID: 4418938
  • Report
  • 172 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AnGes MG Inc
  • Athersys Inc
  • BiogenCell Ltd
  • ID Pharma Co Ltd
  • Miragen Therapeutics Inc
  • Proteon Therapeutics Inc
  • MORE
Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2017, provides an overview of the Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline landscape.

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. Symptoms include painful cramping in hip, thigh or calf muscles after activity, such as walking or climbing stairs (intermittent claudication), leg numbness or weakness, coldness in lower leg or foot, especially when compared with the other side, sores on toes, feet or legs that won't heal, slower growth of toenails and erectile dysfunction in men.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 3, 13, 7, 10 and 2 respectively.

Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peripheral Arterial Disease (PAD) Peripheral Vascular Disease (PVD) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AnGes MG Inc
  • Athersys Inc
  • BiogenCell Ltd
  • ID Pharma Co Ltd
  • Miragen Therapeutics Inc
  • Proteon Therapeutics Inc
  • MORE
Introduction

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development

AnGes MG Inc

AstraZeneca Plc

Athera Biotechnologies AB

Athersys Inc

Bayer AG

Betagenon AB

BiogenCell Ltd

CardioVascular BioTherapeutics Inc

Celgene Corp

Diffusion Pharmaceuticals Inc

Foresee Pharmaceuticals LLC

Hemostemix Inc

ID Pharma Co Ltd

Juventas Therapeutics Inc

LipimetiX Development Inc

Miragen Therapeutics Inc

Novartis AG

Nuo Therapeutics Inc

Proteon Therapeutics Inc

Recardio GmbH

Resverlogix Corp

Sigma-Tau SpA

Stemedica Cell Technologies Inc

Symic Biomedical Inc

VESSL Therapeutics Ltd

ViroMed Co Ltd

Yuyu Pharma Inc

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Drug Profiles

ACP-01 - Drug Profile

AEM-28 - Drug Profile

ALD-301 - Drug Profile

alprostadil - Drug Profile

apabetalone - Drug Profile

BAY-1193397 - Drug Profile

beperminogene perplasmid - Drug Profile

BGC-101 - Drug Profile

Cell Therapy for Peripheral Arterial Disease and Coronary Artery Diseases - Drug Profile

Cell Therapy for Peripheral Arterial Disease and End-Stage Kidney Disease - Drug Profile

CVBT-141C - Drug Profile

Drug for Peripheral Arterial Disease - Drug Profile

DVC-10101 - Drug Profile

ELS-140 - Drug Profile

FP-045 - Drug Profile

JVS-100 - Drug Profile

levocarnitine propionate hydrochloride - Drug Profile

LLG-783 - Drug Profile

MRG-110 - Drug Profile

O-304 - Drug Profile

PC-mAb - Drug Profile

PDA-002 - Drug Profile

PF-05285401 - Drug Profile

REC-03 - Drug Profile

Rejuveinix - Drug Profile

rivaroxaban - Drug Profile

SB-030 - Drug Profile

Stem Cell Therapy for Cardiovascular Disease, Central Nervous System Disorders, Infectious Diseases, Respiratory and Metabolic Disorders - Drug Profile

transcrocetinate sodium - Drug Profile

TXA-127 - Drug Profile

TXA-302 - Drug Profile

V-10 - Drug Profile

VM-202 - Drug Profile

vonapanitase - Drug Profile

YY-984 - Drug Profile

zibotentan - Drug Profile

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2

Number of Products under Development by Companies, H2

Products under Development by Companies, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AnGes MG Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by AstraZeneca Plc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athera Biotechnologies AB, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Athersys Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Bayer AG, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Betagenon AB, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by BiogenCell Ltd, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by CardioVascular BioTherapeutics Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Celgene Corp, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Diffusion Pharmaceuticals Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Foresee Pharmaceuticals LLC, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Hemostemix Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ID Pharma Co Ltd, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Juventas Therapeutics Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by LipimetiX Development Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Miragen Therapeutics Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Novartis AG, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Nuo Therapeutics Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Proteon Therapeutics Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Recardio GmbH, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Resverlogix Corp, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Sigma-Tau SpA, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Stemedica Cell Technologies Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Symic Biomedical Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by VESSL Therapeutics Ltd, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by ViroMed Co Ltd, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline by Yuyu Pharma Inc, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Dormant Projects, H2

Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Discontinued Products, H2

List of Figures

Number of Products under Development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), H2

Number of Products under Development by Companies, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Top 10 Molecule Types, H2

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AnGes MG Inc
  • AstraZeneca Plc
  • Athera Biotechnologies AB
  • Athersys Inc
  • Bayer AG
  • Betagenon AB
  • BiogenCell Ltd
  • CardioVascular BioTherapeutics Inc
  • Celgene Corp
  • Diffusion Pharmaceuticals Inc
  • Foresee Pharmaceuticals LLC
  • Hemostemix Inc
  • ID Pharma Co Ltd
  • Juventas Therapeutics Inc
  • LipimetiX Development Inc
  • Miragen Therapeutics Inc
  • Novartis AG
  • Nuo Therapeutics Inc
  • Proteon Therapeutics Inc
  • Recardio GmbH
  • Resverlogix Corp
  • Sigma-Tau SpA
  • Stemedica Cell Technologies Inc
  • Symic Biomedical Inc
  • VESSL Therapeutics Ltd
  • ViroMed Co Ltd
  • Yuyu Pharma Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll